Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

Launched by ADVANCED RECONSTRUCTIVE SURGERY ALLIANCE · Jun 1, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment for lymphedema, a condition that causes swelling in the arms or legs due to fluid buildup. Currently, there are limited drug options available, and most patients rely on special compression garments to manage their symptoms. The trial focuses on a type of medication called GLP-1 receptor agonists, which are typically used to treat diabetes and obesity. Researchers want to see if these medications can help improve the quality of life and symptoms for people with lymphedema, potentially offering a new treatment option for this challenging condition.

To participate in this study, you need to be an adult aged 18 or older with swelling in one arm or leg that is more than 5% larger than the other limb. You should also have a body mass index (BMI) of 23 or higher and have received clearance from your doctor if you have a history of cancer. However, if you have certain medical conditions, like severe vein problems or have previously had bad reactions to GLP-1 medications, you may not be eligible. If you join the trial, you can expect to receive careful monitoring and support as researchers assess the effects of the medication on your lymphedema symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume \> 5% BMI =\> 23 Oncology clearance if there is a cancer history
• Exclusion Criteria:
• • Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to GLP-1 RAs Medical history or morbidity where GLP-1 RAs are contraindicated as per patient's primary care provider such as MEN syndrome or history of thyroid cancer.